Devalingam Mahalingam, MD
Medical Oncology · Chicago, ILNPI 1164650859
Payments from drug & device makers
Across 787 payments — averaging $9021.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biontech SE$2.3M
- Novartis$1M
- Merck$966K
- Takeda Pharmaceuticals U.S.A., Inc.$451K
- Puma Biotechnology, Inc.$435K
- AbbVie$410K
- plus $1.5M from 15 others
Across 1 payment — averaging $18,183 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AVEO Pharmaceuticals, Inc.$18K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biontech SE | 211 | $2,266,404 |
| Novartis | 9 | $1,031,375 |
| Merck | 19 | $965,592 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $451,476 |
| Puma Biotechnology, Inc. | 31 | $435,133 |
| AbbVie | 106 | $410,165 |
| Genentech, Inc. | 8 | $250,574 |
| Amgen | 37 | $249,468 |
| ADC Therapeutics America, Inc. | 105 | $236,699 |
| Epizyme, Inc. | 16 | $206,078 |
| E.r. Squibb & Sons, L.L.C. | 55 | $183,951 |
| AVEO Pharmaceuticals, Inc. | 3 | $129,870 |
| Bayer | 22 | $92,409 |
| Exelixis Inc. | 86 | $86,478 |
| Eisai Inc. | 42 | $38,482 |
| Pfizer | 2 | $33,239 |
| AstraZeneca | 1 | $29,702 |
| Seagen Inc. | 1 | $1,438 |
| Eli Lilly | 7 | $1,419 |
| Ipsen Biopharmaceuticals, Inc | 3 | $171 |
| Genentech USA, Inc. | 1 | $19 |
How this compares
$7,100,143 in reported general payments places this provider in the 95th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Chicago
- Andrzej JakubowiakChicago$42M
- Alexander PearsonChicago$9.3M
- Jyoti PatelChicago$7.5M
- Ardaman ShergillChicago$4.9M
- Sunandana ChandraChicago$4.6M
- William GradisharChicago$3.3M
- Manali BhaveChicago$3.3M
- Eugene AhnChicago$2.8M
- Nisha MohindraChicago$2.4M
- Jeffrey SosmanChicago$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.